Australia's CSL set for weekly gain on rare diseases drug deal
09/10/2026 02:27
BUZZ-Australia's CSL set for weekly gain on rare diseases drug deal ** Shares of biotech firm CSL CSL.AX up over 4.8% so far this week, on track for best week since mid-September
** On Monday, CSL said it entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion
** Following the deal, brokerage Jefferies raised price target for CSL by 10.2% to A$161.50 on Tuesday
** On Friday, CSL stock rises as much as 1.3% to A$183.9
** Stock up ~6% YTD, including the day's moves
(Reporting by Rudrannsh Mehra in Bengaluru)
Recent news on CSL
See all newsAustralia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine (updated)